Stephens resumed coverage of Alpha Teknova (TKNO) with an Overweight rating and $8 price target The company will benefit from growth in the biologics end market, the analyst tells investors in a research note. The firm believes Alpha continues to add to its clinical solutions customer base, which should drive revenue growth as demand ramps.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TKNO: